BarnettMHPrineasJW. Relapsing and remitting multiple sclerosis: Pathology of the newly forming lesion. Ann Neurol2004; 55(4): 458–468.
2.
KassmannCMLappe-SiefkeCBaesMet al. Axonal loss and neuroinflammation caused by peroxisome-deficient oligodendrocytes. Nat Genet2007; 39(8): 969–976.
3.
TrappBDPetersonJRansohoffRMet al. Axonal transection in the lesions of multiple sclerosis. N Engl J Med1998; 338(5): 278–285.
4.
SormaniMPKapposLRadueE-Wet al. Defining brain volume cutoffs to identify clinically relevant atrophy in RRMS. Mult Scler2017; 23(5): 656–664.
5.
KlistornerAWangCYiannikasCet al. Evidence of progressive tissue loss in the core of chronic MS lesions: A longitudinal DTI study. NeuroImage: Clin2018; 17: 1028–1035.
6.
BarnettMHMatheyEKiernanMCet al. Axonal damage in central and peripheral nervous system inflammatory demyelinating diseases: Common and divergent pathways of tissue damage. Curr Opin Neurol2016; 29(3): 213–221.
7.
YongHChartierGQuandtJ. Modulating inflammation and neuroprotection in multiple sclerosis. J Neurosci Res. Epub ahead of print 5June2017. DOI: 10.1002/jnr.24090.
8.
CadavidDBalcerLGalettaSet al. Safety and efficacy of opicinumab in acute optic neuritis (RENEW): A randomised, placebo-controlled, phase 2 trial. Lancet Neurol2017; 16(3): 189–199.
9.
GreenAJGelfandJMCreeBAet al. Clemastine fumarate as a remyelinating therapy for multiple sclerosis (ReBUILD): A randomised, controlled, double-blind, crossover trial. Lancet2017; 390(10111): 2481–2489.
10.
TourbahALebrun-FrenayCEdanGet al. MD1003 (high-dose biotin) for the treatment of progressive multiple sclerosis: A randomised, double-blind, placebo-controlled study. Mult Scler2016; 22(13): 1719–1731.
